Beta-blocker trial does not reduce risks for COPD patients
COPD is the third leading cause of death worldwide.
New research from scientists at the University of Alabama at Birmingham published in the New England Journal of Medicine has found that beta-blockers used in a clinical trial for patients with chronic obstructive pulmonary disease do not reduce the risk of flare-ups of the disease, also called COPD exacerbations.
COPD is a term used to describe progressive lung diseases including emphysema and chronic bronchitis and is the third leading cause of death worldwide.
"It is well-known that patients who have experienced a heart attack have better outcomes after taking beta-blockers," said study lead author Mark Dransfield, M.D., professor in the UAB Division of Pulmonary, Allergy and Critical Care Medicine. "Beta-blockers protect the heart by lowering pulse and blood pressure. However, we wanted to test the effects of beta-blockers in patients with COPD to see if they could also have a positive impact on the lung disease itself, and specifically whether they would reduce the risk of exacerbations."
Dransfield said, for a long time, people with COPD were not given beta-blockers even when they had heart attacks, because doctors were afraid it would worsen lung function. This continued even though the available data suggests patients with COPD who have heart attacks benefit from beta-blockers just as much as do those without COPD. More recent studies also suggested beta-blockers may reduce mortality and the risk of COPD exacerbations regardless of whether patients had underlying cardiovascular disease.
However, Dransfield said their findings showed no evidence that beta-blockers were helpful in reducing the risk of exacerbations.
"What we found was that beta-blockers don't do anything to reduce the overall risk of exacerbation, but they did increase the rate of severe exacerbations that required hospitalization," he said. "The explanation for the higher risk of COPD hospitalization is not certain, though we did not see any evidence that lung function itself was worsened with beta-blockers."
The 532 participants of the trial ranged from ages 40-85 and had a clinical history of COPD, had at least moderate airflow limitation and were at an increased risk for exacerbation. Patients already taking beta-blockers or who had proven indications for the drugs were excluded, and the results do not directly apply to those groups.
Nearly 12 million people in the United States and roughly 10 percent of the general population in Alabama have been diagnosed with COPD. Smoking in the United States is the most common risk factor among those diagnosed.
Dransfield holds the William C. Bailey Endowed Chair in Pulmonary Disease and is the medical director of the UAB Lung Health Center and UAB Pulmonary Rehabilitation.
More News in Health
New York, Oct 21 (IANS) Adolescents who play contact sports, including football, are no more likely to experience cognitive impairment, depression or suicidal thoughts in early adulthood than their peers, says a new study. Published in
For two Ohio counties, the devil is in the details in a high-stakes, bellwether trial starting today that will decide to what extent opioid distributors can be held responsible for the country's drug
North Carolina health officials say a fourth person has died from Legionnaires' disease. The N.C. Department of Health and Human Resources said in a statement that its Division of Public Health has confirmed 141 cases
Prolonged exposure to blue light may accelerate the aging process and lead to brain damage. Imagining a day without taking a look at your phones or laptop seems impossible today but being
(Reuters) - Opioid deaths in the United States have soared over the last two decades, driving a wave of litigation against drugmakers and distributors. The following is a look at the scale
CLEVELAND (Reuters) - The fight over who is responsible for the opioid epidemic that has ravaged the United States heads to court on Monday in Ohio as local governments seek billions of dollars from companies